Dear Shareholders,
It is with great dedication and a clear vision for the future that I address you as the CEO of Medicortex International AB (publ). For me, as the founder and long-time CEO of Medicortex Finland Oyj, this transition into the Swedish public market represents the most significant milestone in our journey so far. It is a strategic move designed to provide the platform and resources necessary to bring our life-saving technology to the global stage.
A Mission Born from Scientific Innovation
When I founded Medicortex, it was with a singular goal: to revolutionize the way traumatic brain injuries (TBI) are diagnosed. Today, 69 million people suffer from TBIs annually, and staggering 90 percent of these cases are mild injuries (mTBI) that often go undetected by current methods.
Our solution, ProbTBI™, is a breakthrough in medical technology. By developing a non-invasive, portable test that detects specific glycans—carbohydrate biomarkers released when brain cells are damaged—we are enabling diagnosis directly at the point of care, whether on a sports field, a battlefield, or in an emergency room.
Building on a Foundation of Trust and Excellence
We enter this new era as a public company with an exceptionally strong foundation:
The Road Ahead
My commitment as the largest shareholder and CEO remains firm. Our roadmap is clear: we are focused on the further development of our prototypes and our commercialization plan, aiming for a market launch within a few years.
By leveraging our scalable business model—combining outsourced manufacturing with professional global distributors—we are built for rapid growth with controlled capital requirements. I am deeply grateful for your trust as we work to make Medicortex a world leader in brain injury diagnostics.
Adrian Harel, PhD, MBA
CEO and Founder
Medicortex International AB (publ)
Technical Milestones & Patent Portfolio
| Milestone | Description | Status |
| Patent Portfolio | 10 granted patents covering biomarkers and TBI detection methods. | Ongoing Expansion |
| European Patent | Granted in Dec 2025 (EP4483187) for TBI diagnosis using carbohydrate compositions. | Achieved |
| U.S. DoD Funding | Secured 4.9 million EUR across three separate grants for technology development. | Achieved |
| Clinical Validation | Completion of three clinical trials confirming the reliability of glycan biomarkers. | Achieved |
| Prototype Delivery | First-generation prototypes for urine-based testing sent to the U.S. DoD in Feb 2025. | Achieved |
| Product Roadmap | Development of "IndicateTBI" (saliva-based) and second-gen quantitative tests. | In Progress |